Stay updated on AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial

Sign up to get notified when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T00:42:27.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    19 days ago
    Change Detected
    Summary
    The study record page is currently returning a 403 Forbidden error, blocking access to the study details and related information on the page. Users cannot view documents, locations, or other study data.
    Difference
    18%
    Check dated 2026-09-23T01:02:28.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.6 to v3.7.0, indicating a new release of the page or its underlying tooling. This update does not alter the visible study details.
    Difference
    0.0%
    Check dated 2026-09-15T23:57:48.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    A new investigator/location entry Tel Litwinsky, Israel was added, along with a new publication citation related to ATTR-CM attributes. A location entry Qiryat Krinitzi, Israel was removed.
    Difference
    0.1%
    Check dated 2026-09-08T22:30:04.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    Qiryat Krinitzi, Israel was added to the study sites and Tel Litwinsky, Israel was removed. The page revision was updated to v3.6.6.
    Difference
    0.1%
    Check dated 2026-09-01T20:21:56.000Z thumbnail image
  7. Check
    47 days ago
    Change Detected
    Summary
    Added a funding note indicating a 2018 U.S. NIH grant/contract. Added a forthcoming publication citation for Pfister R et al., 'ACO-SWITCH: Rationale and Design of a Phase 4 Study Evaluating Serum Transthyretin in ATTR-CM After Switching from Tafamidis to Acoramidis' in Cardiol Ther, 2026 Aug 20.
    Difference
    0.1%
    Check dated 2026-08-25T20:20:22.000Z thumbnail image

Stay in the know with updates to AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial

Enter your email address, and we'll notify you when there's something new on the AG10 Efficacy & Safety in ATTRibute-CM Clinical Trial page.